Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Regeneron Pharmaceuticals, Inc. (REGN), is a biotechnology company headquartered in Tarrytown, New York, with a market cap of around $82.6 billion. The company specializes in discovering, developing, manufacturing, and commercializing transformative medicines across a broad range of serious diseases, including eye diseases, allergy and inflammation, cancer, cardiovascular, neurological, infectious, hematologic, and rare diseases.

Companies with a market cap of $10 billion or more are typically classified as “large-cap” stocks, and Regeneron Pharmaceuticals comfortably falls within this group. The biotechnology leader is widely recognized for its diverse portfolio of innovative medicines and its development of breakthrough therapies.

Fundamentals

See More
  • Market Capitalization, $K 209,244,640
  • Shares Outstanding, K 539,068
  • Annual Sales, $ 36,751 M
  • Annual Income, $ 7,711 M
  • EBIT $ 9,080 M
  • EBITDA $ 15,447 M
  • 60-Month Beta 0.46
  • Price/Sales 5.69
  • Price/Cash Flow 11.48
  • Price/Book 24.17

Options Overview Details

View History
  • Implied Volatility 27.81% (+2.37%)
  • Historical Volatility 33.02%
  • IV Percentile 57%
  • IV Rank 26.54%
  • IV High 50.37% on 04/08/25
  • IV Low 19.66% on 08/15/25
  • Expected Move (DTE 4) 9.27 (2.39%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 9,653
  • Volume Avg (30-Day) 31,019
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 99,292
  • Open Int (30-Day) 115,218
  • Expected Range 378.90 to 397.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 4.79
  • Number of Estimates 10
  • High Estimate 5.69
  • Low Estimate 4.47
  • Prior Year 4.90
  • Growth Rate Est. (year over year) -2.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
338.07 +14.82%
on 01/30/26
390.14 -0.51%
on 02/27/26
+36.84 (+10.49%)
since 01/27/26
3-Month
312.39 +24.26%
on 12/11/25
390.14 -0.51%
on 02/27/26
+43.59 (+12.65%)
since 11/26/25
52-Week
261.43 +48.48%
on 05/14/25
390.14 -0.51%
on 02/27/26
+82.34 (+26.92%)
since 02/27/25

Most Recent Stories

More News
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.

$NASX : 22,668.21 (-0.92%)
REGN : 781.67 (+1.41%)
AMGN : 388.16 (+2.33%)
Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects

XLV : 160.20 (+1.77%)
AMGN : 388.16 (+2.33%)
PFE : 27.65 (+2.03%)
Is Amgen Stock Outperforming the Dow?

Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.

$DOWI : 48,977.92 (-1.05%)
GILD : 148.95 (+3.60%)
AMGN : 388.16 (+2.33%)
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

THOUSAND OAKS, Calif. , Feb. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 46 th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Kave Niksefat,...

AMGN : 388.16 (+2.33%)
How Is Merck & Co.'s Stock Performance Compared to Other Healthcare Stocks?

Despite Merck & Co.’s strong performance relative to its peers over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects

XLV : 160.20 (+1.77%)
MRK : 123.82 (+3.79%)
AMGN : 388.16 (+2.33%)
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down

1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down

CTOS : 7.16 (-1.78%)
AMGN : 388.16 (+2.33%)
CCO : 2.40 (+0.84%)
1 Momentum Stock to Research Further and 2 We Avoid

1 Momentum Stock to Research Further and 2 We Avoid

PEBO : 32.27 (-2.86%)
AMGN : 388.16 (+2.33%)
FBK : 54.69 (-5.66%)
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

THOUSAND OAKS, Calif. , Feb. 13, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles...

AMGN : 388.16 (+2.33%)
1 Large-Cap Stock Worth Your Attention and 2 We Avoid

1 Large-Cap Stock Worth Your Attention and 2 We Avoid

MDLZ : 61.58 (+2.74%)
FDX : 387.00 (-0.18%)
AMGN : 388.16 (+2.33%)
The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call

The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call

AMGN : 388.16 (+2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 404.01
2nd Resistance Point 397.08
1st Resistance Point 392.62
Last Price 388.16
1st Support Level 381.22
2nd Support Level 374.29
3rd Support Level 369.83

See More

52-Week High 390.14
Last Price 388.16
Fibonacci 61.8% 340.97
Fibonacci 50% 325.79
Fibonacci 38.2% 310.60
52-Week Low 261.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar